

## Multiple Patterns of Resistance to Fluconazole in *Candida glabrata* Isolates from a Patient with Oropharyngeal Candidiasis Receiving Head and Neck Radiation

Spencer W. Redding,<sup>1\*</sup> William R. Kirkpatrick,<sup>2</sup> Stephen Saville,<sup>2</sup> Brent J. Coco,<sup>2</sup> William White,<sup>1</sup> Annette Fothergill,<sup>3</sup> Michael Rinaldi,<sup>3</sup> Tony Eng,<sup>4</sup> Thomas F. Patterson,<sup>2</sup> and Jose Lopez-Ribot<sup>2</sup>

Department of General Dentistry,<sup>1</sup> Department of Medicine, Division of Infectious Diseases,<sup>2</sup> Department of Pathology,<sup>3</sup> and Department of Radiation Oncology,<sup>4</sup> The University of Texas Health Science Center and The South Texas Veterans Healthcare System, San Antonio, Texas 78229-3900

Received 12 August 2002/Returned for modification 18 September 2002/Accepted 8 November 2002

*Candida glabrata* has emerged in recent years as a significant cause of systemic fungal infection. We have previously reported on the first three patients receiving radiation for head and neck cancer to develop oropharyngeal candidiasis due to *C. glabrata*. The goal of this study was to track the development of increased fluconazole resistance in *C. glabrata* isolates and to evaluate previously described genetic mechanisms associated with this resistance from one of these three patients. The patient was a 52-year-old man with squamous cell carcinoma treated with radiation. At week 7 of his radiation, he developed oropharyngeal candidiasis, which was treated with 200 mg of fluconazole daily for 2 weeks. Serial cultures from this and three subsequent time points yielded *C. glabrata*. Isolates from these cultures were subjected to antifungal susceptibility testing, DNA karyotyping, and evaluation of the expression of genes previously associated with *C. glabrata* resistance to fluconazole, *CgCDR1*, *CgCDR2*, and *CgERG11*. Two strains (A and B) of *C. glabrata* were identified and found to display different patterns of resistance development and gene expression. Strain A developed resistance over a 2-week period and showed no overexpression of these genes. In contrast, strain B first showed resistance 6 weeks after fluconazole therapy was discontinued but showed overexpression of all three genes. In conclusion, development of resistance to fluconazole by *C. glabrata* is a highly varied process involving multiple molecular mechanisms.

*Candida glabrata* has emerged in recent years as a significant cause of fungal infections (17). The role of *C. glabrata* in oropharyngeal candidiasis (OPC) is somewhat controversial. When cultured from patients with OPC, this organism is most often detected along with *C. albicans* (17). *C. glabrata* comprises between 5 and 10% of all oral isolates recovered from human immunodeficiency virus (HIV) patients with OPC. In the past, most investigators felt that *C. glabrata* was simply a commensal organism and did not contribute to infection (7). However, OPC infections with mixed *C. albicans* and *C. glabrata* in HIV patients tend to be more clinically severe and require larger doses of fluconazole for clinical cure than infections with *C. albicans* alone (16).

OPC infections due solely to *C. glabrata* have been described. Hoegl et al. reported two such OPC infections in a female HIV-positive drug abuser over a 6-year period (9). Canuto et al. evaluated 179 HIV-positive patients in two Spanish hospitals for risk factors associated with the isolation of fluconazole-resistant oral *Candida* and found that 14% of all the OPC infections were caused by *C. glabrata* (2). *C. glabrata* may be emerging as a potential pathogen in elderly populations. Lockhart et al. reported that 29% of patients older than 80 years were colonized orally with *C. glabrata*. If these patients

wore dentures, the colonization rate increased to 58%. Studies are being done to investigate the rates of OPC due to *C. glabrata* in the elderly (9).

We have previously reported on the epidemiology and clinical course of OPC in patients receiving radiation therapy for head and neck cancer. While *C. albicans* was the primary pathogen, *C. glabrata* was found to be a relatively common colonizing organism in these patients (15). Recently, we described the first three patients to develop OPC due to *C. glabrata*. In one of these patients the *C. glabrata* isolates developed increased microbiological resistance after short-term exposure to fluconazole (18).

Several mechanisms for the development of azole resistance in *C. albicans* have been described. Increased efflux of azole medications from fungal cells has been correlated with the upregulation of multidrug efflux transporter genes, the ATP binding cassette transporters *CDR1* and *CDR2*, and the major facilitator *MDR1* (19, 20). *ERG11*, the gene that codes for the target enzyme of azole medications, lanosterol demethylase, is upregulated along with the development of azole resistance (10). *CDR1*, *MDR1*, and *ERG11* upregulation has also been demonstrated when *C. dubliniensis* develops resistance to fluconazole (14). More recently resistance mechanisms have been investigated for *C. glabrata*. Sanglard et al. have shown upregulation of *CDR1* and *CDR2* when fluconazole MICs rise (21, 22). Marichal et al. have shown an eightfold increase in *ERG11* expression in an azole-resistant *C. glabrata* strain (12).

The goal of this study was to track the epidemiology, using

\* Corresponding author. Mailing address: Department of General Dentistry, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900. Phone: (210) 567-3656. Fax: (210) 567-3662. E-mail: redding@uthscsa.edu.

DNA typing, of the development of fluconazole-resistant *C. glabrata* and to evaluate the previously described genetic mechanisms associated with this resistance on isolates from a patient who developed OPC while receiving radiation to treat head and neck cancer.

#### MATERIALS AND METHODS

The patient was receiving ionizing radiation for head and neck cancer and was participating in a clinical study where patients were given preemptive fluconazole therapy (100 mg/day orally for the duration of radiation) if they had oral culture positive for colonization by *C. albicans* at any time during their radiation therapy. Oral specimens were obtained from the patient and cultured every week for the duration of his radiation treatment. OPC was verified by clinical presentation of white plaques, positive KOH slide, and positive culture. Specimens were collected by using an oral swab and a swish sample of 10 ml of normal saline instilled in the mouth for 10 s and then collected in a sterile container. These samples were plated on blood agar, RPMI medium, and CHROMagar Candida (CHROMagar Co., Paris, France) chromogenic medium. The colony color on chromogenic medium was recorded. Yeasts were identified using standard techniques including analysis of germ tube formation, growth at 37 and 42°C, and identification by API-20C (bioMérieux, Marcy-l'Etoile, France). For all cultures, three to five yeast colonies from primary plates were selected and stored on Sabouraud dextrose slants for antifungal susceptibility testing and DNA typing.

Broth microdilution antifungal susceptibility testing to fluconazole was performed by the Fungus Testing Laboratory, University of Texas Health Science Center at San Antonio. The NCCLS-approved method for fungal drug susceptibility, involving a broth microdilution method with RPMI 1640 medium (Angus Buffers, Niagara Falls, N.Y.) buffered to pH 7.0 with MOPS (3-[N-morpholino]propanesulfonic acid) with an inoculum of  $0.5 \times 10^3$  to  $2.5 \times 10^3$  cells per ml, was used (13). Specifically, five colonies of each isolate were selected, placed in medium with MOPS, and diluted to the desired concentration using spectrophotometric techniques. Serial dilutions of drugs were made from 0.03 to 128  $\mu\text{g/ml}$ , the yeast cell inoculum was added, and the mixture was incubated at 35°C for 48 h. Following incubation, the growth in each well was scored as follows: 0, optically clear; 1+, slightly hazy; 2+, prominent reduction in turbidity compared with that of the drug-free control (80% inhibition end point); 3+, slight reduction in turbidity compared with that of the drug-free control; 4+, no reduction in turbidity compared with that of the drug-free control. As recommended by Espinel-Ingroff et al., the MIC of azoles is defined as the lowest concentration in which the growth score was 2+ (80% inhibition) or less following 48 h of incubation (6). The intralaboratory reproducibility of this method has been shown to be >95% within a fourfold concentration range. Thus, significant changes in the MICs are considered to occur when the MIC increases twofold or more for serial isolates tested in parallel.

Strain identity was established by electrophoretic karyotyping (EK). Chromosomal DNA from each isolate was prepared in agarose plugs and separated by pulsed-field gel electrophoresis with a CHEF-DRIII instrument (Bio-Rad, Hercules, Calif.). Briefly, yeast DNA in 0.75% agarose plugs was resolved on a 1% agarose gel by contour-clamped homogenous electric field (CHEF) gel electrophoresis in  $0.5 \times$  Tris-borate-EDTA buffer at 14°C. The running conditions for EK were as follows: block I, 120 s 4.5 V/cm 22 h; block II, 300 s 4.5 V/cm 5 h; block III, 300 s 3.4 V/cm 23 h. Gels were stained with ethidium bromide (1  $\mu\text{g/ml}$ ) and photographed (5). Fingerprints were considered highly similar when all visible bands showed the same migration distance for each isolate. Variations in the intensity and shape of bands among isolates were not considered differences. The presence or absence of more than one distinct band was considered a difference (11).

The expression patterns of the known *C. glabrata* resistance-associated genes *Cg CDR1*, *Cg CDR2*, and *Cg ERG11* were determined by Northern blot analyses. Each of the clinical isolates was mechanically disrupted in TRI reagent (Molecular Research Center, Cincinnati, Ohio) using a mini-beadbeater (Biospec Products, Bartlesville, Okla.), and total RNA was precipitated from the resulting supernatant with isopropyl alcohol. Approximately equal amounts of RNA obtained from each isolate were resolved on formaldehyde-agarose gels and subsequently transferred to Nytran supercharged membranes by using a Turboblotter (Schleicher & Schuell, Keene, N.H.) as specified by the manufacturer.

DNA probes for the *C. glabrata* genes *Cg CDR1*, *Cg CDR2*, and *Cg ERG11* were PCR amplified from genomic DNA prepared from one of the strain A isolates using primers designed from their GenBank database entries (accession numbers AF109723, AF251023 and LF40389, respectively). Hybridizations were performed by the method of Church and Gilbert (3), with all blots washed to high

Isolate:	6837	6838	6843	6844	6855	6856	6954	6955
MIC:	8	8	32	8	>64	8	>64	64
Pattern:	A	B	A	B	A	B	A	B
Visit:	7	7	8	8	9	9	10	10




FIG. 1. EK patterns and MICs of fluconazole for strains A and B from visits 7 through 10.

stringency (40 mM  $\text{Na}_2\text{HPO}_4$ -0.1% sodium dodecyl sulfate at 65°C) and exposed to X-ray film at room temperature overnight.

#### RESULTS

The patient was a 52-year-old man diagnosed with squamous cell carcinoma of the floor of the mouth, stage T4N2bM0, treated with 5,910 cGy of radiation over a 9-week period. At visits 3 through 6, his oral cultures grew *C. glabrata* and/or *C. krusei* but he exhibited no clinical disease. He was not given fluconazole because he had not been culture positive for *C. albicans*. At visit 7 he presented with white plaques on his oral mucosa that were KOH positive, and swab and swish cultures were plated on CHROMagar Candida to help with identification. The predominant growth on his swab plate and the only growth on his swish plate were lavender colonies consistent with *C. glabrata*. There were a few beige colonies on the swab culture consistent with *C. krusei*. The predominant organism was confirmed to be *C. glabrata*. The patient was given 200 mg of fluconazole per day based on screening results from CHROMagar Candida containing various concentrations of fluconazole. CHEF karyotypes showed two *C. glabrata* strains (A and B), both of which had 48-h fluconazole MICs of 8.0  $\mu\text{g/ml}$  (Fig. 1). At visit 8, there were no clinical signs of OPC but colonization cultures were again positive primarily for *C. glabrata* with a few colonies of *C. krusei*. The fluconazole MICs for *C. glabrata* strains A and B were now 32.0 and 8.0  $\mu\text{g/ml}$ , respectively. Fluconazole therapy was continued. Visit 9 was made at the conclusion of radiation therapy. At that visit, there was no sign of OPC and the fluconazole therapy was discontinued. Colonization cultures showed the same pattern of *C. glabrata* and *C. krusei* as seen at visit 8. Fluconazole MICs for strains A and B were now 64.0 and 8.0  $\mu\text{g/ml}$ , respectively. Visit 10 was a 6-week follow-up after radiation therapy, and the fluconazole therapy had been discontinued. The colonization culture grew only *C. glabrata*. Fluconazole MICs for strains A and B were both 64.0  $\mu\text{g/ml}$  (Fig. 2).

As with antifungal susceptibility, strains A and B showed




FIG. 2. Graph of the increase in the fluconazole MICs for strains A and B from visits 7 through 10. \*, visit occurred 6 weeks after cessation of treatment.

very different expression patterns of Cg *CDR1*, Cg *CDR2*, and Cg *ERG11*. Expression did not change in the serial isolates of strain A even after the fluconazole MICs rose from 8.0 to 64 µg/ml. Strain B showed no change in gene expression of Cg *CDR* or Cg *CDR2* from visits 7 to 9, when the fluconazole MIC remained at 8.0 µg/ml. Expression of Cg *ERG11* appeared to drop at visit 9. However, at visit 10 strain B showed overexpression of all three genes tested, corresponding to the increased fluconazole resistance from 8 to 64 µg/ml (Fig. 3).

DISCUSSION

*C. glabrata* has recently emerged as a significant systemic pathogen, and there are increasing numbers of reports that it causes oral disease. It has been shown typically to have increased fluconazole MICs compared with *C. albicans*, and these MICs can rise rapidly when the organism is exposed to fluconazole (17, 18).

The purpose of this study was to evaluate the molecular mechanisms involved in the development of resistance by *C. glabrata* after fluconazole treatment of an oral infection in a patient receiving radiation for head and neck cancer. This




FIG. 3. Expression patterns of known *C. glabrata* resistance-associated genes in the serial isolates of strains A and B. Total RNA was prepared from each isolate and probed with PCR-amplified fragments of the *C. glabrata* Cg *CDR1*, Cg *CDR2*, and Cg *ERG11* genes by Northern blot analysis. The rRNA bands of the blotted gels are shown to demonstrate the roughly equal loading of the samples.

patient could be said to have had a mixed infection since a few colonies of *C. krusei* grew on the swab culture. However, *C. glabrata* predominated on the swab culture and was present alone on the swish culture. Also, this patient responded to a dose of fluconazole (200 mg/day) that is well suited to treat an organism generally considered to be susceptible or dose-dependent susceptible to fluconazole, as is the case for *C. glabrata*, but not well suited to treat an inherently fluconazole-resistant organism such as *C. krusei*. Therefore, we feel that this infection was caused by *C. glabrata* and the patient was colonized by *C. krusei*. However, we cannot rule out the possibility of a mixed infection.

Matched sets of susceptible and resistant isolates are required to evaluate molecular mechanisms of resistance. EK was used to show the strain relatedness of susceptible and resistant isolates in this patient since it is the most reliable technique to type *C. glabrata* (1, 4). Two isogenic strains were cultured that persisted over time and became resistant after exposure to fluconazole.

The two strains displayed increased microbiological resistance after short-term exposure to fluconazole, but in two very different patterns. After 2 weeks of fluconazole treatment, the MIC for strain A increased from 8.0 to 64.0 µg/ml but the MIC for strain B remained constant at 8.0 µg/ml. At a 6-week follow-up, the resistance of strain A remained stable (MIC, 64.0 µg/ml) but the MIC for strain B was now also at 64.0 µg/ml. Interestingly, even with these rises in MIC, the patient responded to 200 mg of fluconazole per day and did not relapse with the increase in MIC. NCCLS document M27-A has proposed interpretive breakpoints for *Candida* tested against fluconazole, with MICs below 16 µg/ml indicating susceptibility and MICs above 32.0 µg/ml indicating resistance (13). It is possible that strain B was the predominant strain in the clinical infection and remained susceptible while the infection was being treated, showing a rise in the fluconazole MIC only a long time after the infection had responded to therapy. The risk of developing OPC falls after radiation therapy has been completed. Also, most of the patient data evaluated for the NCCLS breakpoints were obtained from patients with HIV or other immunocompromising conditions. Patients receiving head and neck radiation alone are not generally immunosuppressed and may be better able to clear OPC at modestly increased doses of fluconazole.

Resistance to fluconazole can be induced by the following mechanisms: (i) accumulation of the drug in the cell can be impaired; (ii) the *ERG11* content of the cell can be elevated; (iii) point mutations in *ERG11* may decrease the affinity for fluconazole; and (iv) the ergosterol biosynthetic pathway may be altered (23). We evaluated three genes that have been previously described to be upregulated in resistant isolates of *C. glabrata*, Cg *CDR1*, Cg *CDR2*, and Cg *ERG11*. Like the MIC patterns, the patterns of gene expression were very different between the two strains. Surprisingly, strain A showed no upregulation of Cg *CDR1*, Cg *CDR2*, and Cg *ERG11* when the fluconazole MIC rose to 64 µg/ml. Other mechanisms apparently are in operation for this strain. However, we specifically limited our examination to these three genes, since they are, so far, the only ones to have been definitively associated with the development of fluconazole resistance in *C. glabrata*. Another factor is that while MDR1 is a major player in the development

of fluconazole resistance in *C. albicans*, to our knowledge neither it nor any other member of the major facilitator superfamily has yet been described in *C. glabrata* (as indicated by current entries in the GenBank database). That such homologues exist and may be involved in acquired fluconazole resistance in some instances in *C. glabrata* is not in doubt. However, this is also likely to be true for many of the “drug” efflux pumps which have been characterized in *C. albicans* but remain to be discovered in *C. glabrata*. We feel that identifying the *C. glabrata* homologue of every one of these genes and examining their expression profile is beyond the scope of this study and still may not reveal the nature of the fluconazole resistance which developed in strain A. Other resistance mechanisms may include *ERG11* point mutations and ergosterol pathway alterations. We hope to evaluate strain A for these potential other mechanisms in the future. In contrast, strain B was much more consistent with patterns for *C. glabrata* found by other investigators, since overexpression of all three genes in this strain closely matched the rise in MIC. Interestingly, expression of Cg *ERG11* appeared to drop after the 2-week treatment with fluconazole but then the gene became overexpressed after 6 weeks of no fluconazole exposure.

It is difficult to determine the clinical significance of the development of resistance in these *C. glabrata* isolates. Infection was controlled with a fluconazole dose of 200 mg/day, which was consistent with the baseline MIC. If, as mentioned above, strain B was the pathogenic strain, the genes upregulated when this strain developed resistance appeared to be involved in the clinically important mechanisms in this patient.

In conclusion, we have evaluated the epidemiology of the development of resistance to fluconazole by two different strains of *C. glabrata* in a patient with OPC who was receiving radiation for head and neck cancer. We have also investigated the expression of three genes previously described as important for the development of this resistance, Cg *CRD1*, Cg *CDR2*, and Cg *ERG11*. Our results showed highly varied patterns since one strain showed no overexpression of the three genes tested with the development of resistance whereas the other strain showed overexpression of all three. This patient is only one patient infected with two strains of *C. glabrata*, and it is premature to speculate about the relative importance of our findings to the understanding of the resistance mechanisms operant in this organism. It is clear that development of resistance to fluconazole by *C. glabrata* is a highly varied process involving multiple molecular mechanisms, some of which remain to be determined.

#### ACKNOWLEDGMENTS

This work was supported by a grant from Pfizer, Inc., Public Health Service grant 5-R01-DE11381-6 from the National Institutes of Health, and the Dental Oncology Education Program.

#### REFERENCES

1. Barchiesi, F., L. Di Francesco, D. Arzeni, F. Caselli, D. Gallo, and G. Scalise. 1999. Electrophoretic karyotyping and triazole susceptibility of *Candida glabrata* clinical isolates. *Eur. J. Microbiol. Infect. Dis.* **18**:184–187.
2. Canuto, M. M., F. G. Rodero, V. O. Ducasse, I. H. Aguado, C. M. Gonzalez, A. S. Sevillano, and A. M. Hildalgo. 2000. Determinants for the development

- of oropharyngeal colonization or infection by fluconazole-resistant *Candida* strains in HIV-infected patients. *Eur. J. Clin. Microbiol. Infect. Dis.* **19**:593–601.
3. Church, G. M., and W. Gilbert. 1984. Genomic sequencing. *Proc. Natl. Acad. Sci. USA* **81**:1991–1995.
4. Di Francesco, L., F. Barchiesi, F. Caselli, O. Cirioni, and G. Scalise. 1999. Comparison of four methods for DNA typing of clinical isolates of *Candida glabrata*. *J. Med. Microbiol.* **48**:955–963.
5. Doebbling, B. N., R. F. Lehmann, R. J. Hollis, L. C. Wu, A. F. Widmer, A. Voss, and M. A. Pfaller. 1993. Comparison of pulsed-field gel electrophoresis with isoenzyme profiles as a typing system for *Candida tropicalis*. *Clin. Infect. Dis.* **16**:377–383.
6. Espinel-Ingroff A., C. W. Kish, Jr., T. M. Kerkerling, R. A. Fromtling, K. Bartizal, and J. N. Galgiani. 1992. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. *J. Clin. Microbiol.* **30**:3138–3145.
7. Fidel, P. L., J. A. Vazquez, and J. D. Sobel. 1999. *Candida glabrata*: review of epidemiology, pathogenesis, and clinical disease with comparison to *C. albicans*. *Clin. Microbiol. Rev.* **12**:80–96.
8. Hoegl, L., E. Thoma-Greber, M. Röcken, and H. Korting. 1998. Persistent oral candidosis by non-*albicans* *Candida* strains including *Candida glabrata* in a human immunodeficiency virus-infected patient observed over a period of 6 years. *Mycoses* **41**:335–338.
9. Lockhart, S. R., S. Joly, K. Vargas, J. Swails-Wenger, and D. R. Soll. 1999. Natural defenses against *Candida* colonization breakdown in the oral cavities of the elderly. *J. Dent. Res.* **78**:857–868.
10. Lopez-Ribot, J. L., R. K. McAtee, L. Lee, W. R. Kirkpatrick, T. C. White, D. Sanglard, and T. F. Patterson. 1998. Distinct patterns of gene expression associated with the development of fluconazole resistance in serial *Candida albicans* isolates from HIV infected patients with oropharyngeal candidiasis. *Antimicrob. Agents Chemother.* **42**:2932–2937.
11. Magee, P. T., L. Bowdin, and J. Staudinger. 1992. Comparison of molecular typing methods for *Candida albicans*. *J. Clin. Microbiol.* **30**:2674–2679.
12. Marichal, P., H. Vanden Bossche, F. C. Odds, G. Nobels, D. W. Warnock, V. Timmerman, C. Vanbroeckhoven, S. Fay, and P. Mosel-Larsen. 1997. Molecular characterization of an azole-resistant *Candida glabrata* isolate. *Antimicrob. Agents Chemother.* **41**:2229–2237.
13. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. Perea, S., J. L. Lopez-Ribot, B. L. Wickes, W. R. Kirkpatrick, O. P. Dib, S. P. Bachmann, S. M. Keller, M. Martinez, and T. F. Patterson. 2002. Molecular mechanisms of fluconazole resistance in *Candida dubliniensis* isolates from human immunodeficiency virus infected patients with oropharyngeal candidiasis. *Antimicrob. Agents Chemother.* **46**:1695–1703.
15. Redding, S. W., R. C. Zellars, W. R. Kirkpatrick, R. K. McAtee, M. A. Caceres, A. W. Fothergill, J. L. Lopez-Ribot, C. W. Bailey, M. G. Rinaldi, and T. F. Patterson. 1999. Epidemiology of oropharyngeal *Candida* colonization and infection in patients receiving radiation for head and neck cancer. *J. Clin. Microbiol.* **37**:3896–3900.
16. Redding, S. W., W. R. Kirkpatrick, O. P. Dib, A. W. Fothergill, M. G. Rinaldi, and T. F. Patterson. 2000. The epidemiology of non-*albicans* *Candida* in oropharyngeal candidiasis in HIV patients. *Spec. Care Dent.* **20**:178–181.
17. Redding, S. W. 2001. The role of yeasts other than *Candida albicans* in oropharyngeal candidiasis. *Curr. Opin. Infect. Dis.* **14**:673–677.
18. Redding, S. W., W. R. Kirkpatrick, B. J. Coco, L. Sadkowski, A. W. Fothergill, M. G. Rinaldi, T. Y. Eng, and T. F. Patterson. 2002. *Candida glabrata* oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. *J. Clin. Microbiol.* **40**:1879–1881.
19. Sanglard, D., K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in *Candida albicans* isolates from AIDS patients involve specific multidrug transporters. *Antimicrob. Agents Chemother.* **39**:2378–2386.
20. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1997. Cloning of *Candida albicans* genes conferring resistance to antifungal agents: characterization of *CDR2*, a new multidrug ABC-transporter gene. *Microbiology* **143**:405–416.
21. Sanglard, D., F. Ischer, D. Calabrese, P. Majcherzyk, and J. Bille. 1999. The ATP binding cassette transporter gene *CDR1* from *Candida glabrata* is involved in the resistance of clinical isolates to azole antifungal agents. *Antimicrob. Agents Chemother.* **43**:2753–2765.
22. Sanglard, D., F. Ischer, and J. Bille. 2001. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in *Candida glabrata*. *Antimicrob. Agents Chemother.* **45**:1174–1183.
23. Sanglard, D., and J. Bille. 2002. Action of and resistance to antifungal agents, p. 349–383. *In* R. A. Calderone (ed.), *Candida* and candidiasis. ASM Press, Washington, D.C.